Mutations in TTN, MUC16, and DNAH5 were higher in patients in cluster A than in those in cluster B. Patients in cluster A had a higher tumor mutation load and were likely to produce more neoantigens, resulting in patients benefiting more from immunotherapy, which also verified that inflammatory tumors were more sensitive to immune checkpoint inhibitors. Here, MUC16 is linked to neoplasm.